Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 13/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526718 | 0.93 | ADORA2A (0.39) | ADORA2BADORA1ADORA2AADORA3ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL562010 | 0.93 | SMN1; SMN2 (0.39) | ADORA2BADORA1ADORA2AADORA3HDAC1 | |
| Trifluoroacetic Acid SCHEMBL563552 | 0.91 | ADORA2B (0.39) | ADORA2BADORA1ADORA2AADORA3HDAC1 | |
| Trifluoroacetic Acid SCHEMBL562818 | 0.90 | ADAMTS4 (0.39) | ADORA2BADORA1ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL562106 | 0.90 | PPARA (0.46) | ADORA2BADORA1ADORA2AADORA3HDAC1 | |
| Trifluoroacetic Acid SCHEMBL562778 | 0.89 | APLNR (0.38) | ADORA2BADORA1ADORA2AADORA3ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL563145 | 0.87 | ADORA2B (0.39) | ADORA2BADORA1ADORA2AADORA3HDAC1 | |
| Trifluoroacetic Acid SCHEMBL563327 | 0.87 | ADORA2B (0.38) | ADORA2BADORA1ADORA2AADORA3HDAC1 | |
| Trifluoroacetic Acid SCHEMBL563103 | 0.87 | ADORA2A (0.33) | ADORA2BADORA1ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL562727 | 0.86 | PPARA (0.45) | ADORA2BADORA1ADORA2AADORA3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371216-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2014-12-18 | — | — | US | disclosed |
| US-8703783-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | INCYTE CORPORATION (US) | 2012-02-09 | — | — | US | disclosed |
| US-8039478-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090286774-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| EP-2044074-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | Incyte Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7511050-B2 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007150025-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371216-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885ADORA1 39/4885ADORA2A 12/4885 |
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885ADORA1 39/4885ADORA2A 12/4885 |
| US-20090286774-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885ADORA1 39/4885ADORA2A 12/4885 |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | HMGCR, LDLR, GPBAR1 | ADORA2B 177/4885ADORA1 50/4885ADORA2A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.